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proteome and EGFR pathway contribute to
hypertrophic cardiomyopathy
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Mingguo Xu1,2,13, Kevin C. Bermea 1,13, Marzieh Ayati3,13, Han Byeol Kim4, Xiaomei Yang5, Andres Medina6,
Zongming Fu7, Amir Heravi1, Xinyu Zhang8, Chan Hyun Na 4,9, Allen D. Everett1, Kathleen Gabrielson10,
D. Brian Foster 11, Nazareno Paolocci11,12, Anne M. Murphy1 ✉ & Genaro A. Ramirez-Correa 1,6 ✉

Alterations of serine/threonine phosphorylation of the cardiac proteome are a hallmark of
heart failure. However, the contribution of tyrosine phosphorylation (pTyr) to the pathogenesis of cardiac hypertrophy remains unclear. We use global mapping to discover and
quantify site-speciﬁc pTyr in two cardiac hypertrophic mouse models, i.e., cardiac overexpression of ErbB2 (TgErbB2) and α myosin heavy chain R403Q (R403Q-αMyHC Tg),
compared to control hearts. From this, there are signiﬁcant phosphoproteomic alterations in
TgErbB2 mice in right ventricular cardiomyopathy, hypertrophic cardiomyopathy (HCM), and
dilated cardiomyopathy (DCM) pathways. On the other hand, R403Q-αMyHC Tg mice
indicated that the EGFR1 pathway is central for cardiac hypertrophy, along with angiopoietin,
ErbB, growth hormone, and chemokine signaling pathways activation. Surprisingly, most
myoﬁlament proteins have downregulation of pTyr rather than upregulation. Kinasesubstrate enrichment analysis (KSEA) shows a marked downregulation of MAPK pathway
activity downstream of k-Ras in TgErbB2 mice and activation of EGFR, focal adhesion, PDGFR,
and actin cytoskeleton pathways. In vivo ErbB2 inhibition by AG-825 decreases cardiomyocyte disarray. Serine/threonine and tyrosine phosphoproteome conﬁrm the abovedescribed pathways and the effectiveness of AG-825 Treatment. Thus, altered pTyr may play
a regulatory role in cardiac hypertrophic models.
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amilial hypertrophic cardiomyopathy (HCM) increases the
left ventricle (LV) wall thickness; abnormal loading conditions cannot explain this alteration. Mutations in genes
encoding sarcomere proteins are common in HCM patients
(40–60%)1. Studying post-translational modiﬁcations (PTMs) of
the sarcomere proteins (or Ca2+ handling proteins) can offer a
unique opportunity to understand better how genetic disorders
lead to cardiac dysfunction and discover potential targets for
therapy2–4. For instance, PTMs of cardiac Troponin I (cTnI), a
sarcomere protein centrally involved in myocardial contractility
regulation, have been extensively studied, particularly for the
functional role of protein kinase A-dependent phosphorylation5.
Notably, phosphorylation of cTnI-S22/23—one of the most
relevant regulatory sites of cTnI—is downregulated in human
heart failure (HF)6 and leads to contractile dysfunction7.
Tyrosine phosphorylation (pTyr) is essential for cardiac
structural development and myoﬁbril organization during
embryogenesis8,9. For example, several tyrosine phosphatases
have been linked to heart disease and even proposed as a therapeutic target for some conditions. Moreover, mutations of the
tyrosine-protein phosphatase non-receptor type 11 (PTPN11) can
lead to HCM or dilated cardiomyopathy (DCM)10,11. In the heart,
PTPN11 likely plays a role in systolic dysfunction produced by
pressure-overload12. Acid phosphatase 1 (ACP1) is another tyrosine phosphatase associated with cardiac pathophysiology.
Accordingly, its deletion protects against stress-induced
cardiomyopathy13. Our group ﬁrst showed that cTnI-Y26 phosphorylation is readily detected in healthy human hearts and
downregulated in human HF and DCM14. However, how these
alterations contribute to the onset and progression of cardiac
disease remains poorly understood. A better grasp of additional
site-speciﬁc changes of individual tyrosine-phosphorylated sites
would help in this direction substantially.
The present study applied a label-free and tandem mass tagging (TMT) quantitative global phosphotyrosine proteomics
approach to determine which sarcomere sites have altered
amounts of Tyr phosphorylation at speciﬁc sites in two unrelated
models of HCM. The ﬁrst model is secondary to the overexpression of the tyrosine kinase receptor ErbB215,16. The second
recapitulates features of the human disease, more speciﬁcally, an
R403Q mutation of the myoﬁlament protein myosin heavy chain,
distinctive of familial HCM17. TgErbB2 mice initially develop a
striking, concentric cardiac hypertrophy, which evolves to diffuse
ﬁbrosis and myocyte disarray16 with HCM. This line of mice also
has abnormal calcium handling, is prone to arrhythmias, and to
developing hypertrophic obstructive cardiomyopathy2. Similarly,
R403Q-αMyHC mice reproduce human familial HCM by progressing from mild hypertrophy and ﬁbrosis to overt myocyte
disarray, HF, and arrhythmias17.
The main impetus behind this study was to determine whether
triggering HCM through different mechanisms elicits similar
pTyr-related pathways/regulatory sites within the heart. In doing
so, the manipulation of these pTyr sites would, in turn, offer new
opportunities for therapeutic targeting in different forms of
human HCM
Results
Immunoblotting reveals decreased cardiac pTyr in HCM
models. First, we performed immunoblot analysis of the myocardium of TgErbB2, R403Q-αMyHC, and non-transgenic (Ntg)
mice to estimate pTyr. There was a global decline in pTyr in
whole heart homogenates of TgErbB2 (p = 0.0298) and R403QαMyHC (p = 0.003) mice compared to Ntg (Fig. 1a, b). The pTyr
signal was normalized to troponin I expression levels (Fig. 1a).
Although proto-oncogene tyrosine-protein kinase Src (c-Src) is
2

downstream of ErbB2 signaling, we did not anticipate its
increased expression in R403Q-αMyHC mice (Fig. 1c, d,
p = 0.0414) when normalized to GAPDH western blot signals.
The c-Src activity (c-Src Tyr416 phosphorylation) appeared to be
enhanced in R403Q-αMyHC mice compared to Ntg; however, it
did not reach statistical signiﬁcance (Fig. 1e, f, one-way ANOVA
was used to compare groups). Altogether these data suggest that
pTyr is a broadly distributed PTMs in the myocardium. Hence, its
upregulation or downregulation may play a regulatory role in the
disease progression of non-ischemic cardiomyopathies, as in
the case of familial cardiomyopathy (HCM) and DCM, as part of
the pathophysiologic response to the underlying disease.
pTyr in myoﬁlaments and cross-talk with serine/threonine
kinases/phosphatases. Next, we adopted a global TMT phosphotyrosine proteomic approach to compare the whole heart pTyr
proﬁle of Ntg, TgErbB2, and R403Q-αMyHC mice (Fig. 2). We
hypothesized that unbiased global whole heart pTyr proﬁling
would provide a complete landscape about speciﬁc tyrosine sites
in essential cardiac-speciﬁc proteins and tyrosine kinases, thus
providing clues about which tyrosine kinases mediate cardiac
pTyr. A total of 1,800 peptide spectra matched (PSM) were collected from the heart ventricle whole proteome, and 50% were
identiﬁed with high conﬁdence resulting in 213 (R403QαMyHC), 214 (Ntg), 217 (TgErbB2) unique tyrosinephosphorylated peptides corresponding to 499 proteins
(Fig. 2g). Tables with all identiﬁed phosphoproteins and phosphopeptides are provided in Supplementary Data 3. The mass
spectrometry data quality, intensity, and distribution post-median
sweep normalization are included in Supplementary Fig. 1a, b.
Conﬁdence of phosphorylated site localization was evaluated for
annotation, and a score of more than 49% was required. This
dataset indicates a comparable yield of peptide identiﬁcation was
achieved, reproducibility on the enrichment of pTyr peptides, and
high-quality MS/MS data using similar approaches to others18–20.
The global TMT phospho-tyrosine proteomics approach
identiﬁed 499 different tyrosine-phosphorylated proteins, 294
tyrosine-phosphorylated proteins that overlap among the Ntg,
and the myocardium from two cardiac hypertrophic models
(TgErbB2 and R403Q-αMyHC). At the peptide level, 217 pTyr
sites were detected with an overlap of 178 tyrosinephosphorylated residues (Fig. 2g, h).
Next, the focus was on the cardiac-speciﬁc proteins from the
myoﬁlament apparatus. Nine major myoﬁlament proteins were
tyrosine-phosphorylated. They harbor multiple pTyr amino acid
sites, many of which are novel (See Supplementary Fig. 2); the
best example is Titin, with 36 pTyr amino acid sites (See
Supplementary Fig. 3). Also, seventeen tyrosine kinases had
detectable tyrosine-phosphorylated peptides; thus, they could
potentially be involved in regulating cardiac myoﬁlament pTyr.
In contrast, only two tyrosine phosphatases (Ptpn11 and Ptpra)
had detectable tyrosine-phosphorylated peptides; therefore, they
are likely to play a role in regulating cardiac pTyr levels in the
sarcomere. In addition to the number of tyrosine kinases found
with phosphorylated peptides, ﬁfteen serine/threonine kinases
had detectable tyrosine-phosphorylated peptides; however, only
one serine/threonine phosphatase (Ppp1r12b) demonstrated
tyrosine-phosphorylated peptides. These data show that pTyr is
broadly distributed in the heart proteome (cardiac sarcomere and
other sub-proteomes) and that a cross-talk between tyrosine
kinases/phosphatases with serine/threonine kinases/phosphatases
might be regulating cardiac sarcomere pTyr.
ErbB2 cardiac overexpression and R403Q-αMyHC point
mutation remodeled the cardiac pTyr proteome. Next, we
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Fig. 1 Global pTyr is reduced in cardiac hypertrophy associated with ErbB2 overexpression or myosin heavy chain mutation. a Western Blots show a
decrease in pTyr on TgErbB2 (p = 0.0298) mice and R403Q-α-MyHC (p = 0.003) heart homogenates. The Troponin I signal shows corresponding total
protein loading. b Densitometry analysis shows that after the pTyrosine signal was normalized to total cTnI, the TgErbB2 and R403Q-α-MyHC mice
signiﬁcantly decreased in pTyr. c Western Blots show expression levels of total Src and p-Src (Tyr 416) and GAPDH as a loading control. d Densitometry
analysis revealed that Src levels are signiﬁcantly elevated in R403Q-α-MyHC (p = 0.0282), whereas e and f Show that p-Src phosphorylation levels are
elevated in R403Q-α-MyHC but did not reach statistical signiﬁcance. Signals in d and e were normalized to total GAPDH, whereas in f pSRC was
normalized to total SRC. Ntg (n = 3), TgErbB2 (n = 3), and R403Q-α-MyHC (n = 3), error bars represent S.E.M. One-way ANOVA was used to compare
groups.

undertook bioinformatic analyses to deﬁne the impact of ErbB2
cardiac overexpression and R403Q mutation of the cardiac
myosin heavy chain on the speciﬁc pTyr changes. We determined the signaling transduction pathways associated with two
unrelated types of HCM. Spectral signal normalization of pTyr
was performed over the whole global heart TMT isobaric probes
that quantiﬁed full proteome (Fig. 2e, f), and statistical methods
were performed, as previously described21,22. Then, principal
component analysis (PCA) and hierarchical clustering were
applied to determine if the pTyr proﬁles were similar within the
groups. This approach revealed that the three groups segregate
by principal component 1 (PC1 = 46%) in full proteome
quantiﬁcation (Fig. 3a). This ﬁnding was also evident after pTyr
normalization to full proteome; the three groups segregate along
the principal component (PC1 = 52.2%) (Fig. 3b). Of note, one
technical/biological replicate of R403Q-αMyHC was removed
because it had more than 50% absent pTyr peptides compared
to the other two replicates. Hence, it was considered a technical
failure. Heatmaps of hierarchically clustered up- or downregulated normalized pTyr peptides helped visualize the technical reproducibility and the speciﬁcity of how the genotype of
cardiac hypertrophy largely inﬂuenced the pTyr proteome
remodeling (Fig. 3c, p < 0.05 by ANOVA). Tyrosinephosphorylated peptides are color-coded according to their
extracted chromatogram MS1 signal intensities normalized to
TMT isobaric label peptide MS2 intensity. Yellow is upregulated, and blue is downregulated. This approach provided us
with the global heart proteome tyrosine peptide abundance.
These results demonstrate that Ntg, TgErbB2, and R403QαMyHC mice have a pTyr proteome with a distinct signature,

evidenced by PCA and heatmaps clustering in unsupervised
unbiased statistical methods.
Statistically signiﬁcant changes (Log2 fold change >1, -Log pvalue < 1.3) were detected in 23 phosphosites corresponding to 18
proteins in TgErbB2 mice (Fig. 3d) and 45 phosphosites in 35
proteins in the R403Q-αMyHC Tg mice (Fig. 3f) using ANOVA
(p < 0.05). It is noteworthy that pTyr of several peptides of the
alpha-myosin heavy chain (Myh7-Y386, Y410, Y1375), one
peptide of the beta-myosin heavy chain (Myh6-Y1349), and two
peptides of Titin (Ttn-Y2118, Y21190) are downregulated while
cardiac Ttn Y-31324 pTyr is upregulated on TgErbB2 mice hearts
(Fig. 3d). Interestingly, Myh7-Y410 phosphorylation is downregulated in TgErbB2 and upregulated in R403Q-αMyHC Tg
mice hearts (Fig. 3e). In contrast, cTnI Y113 (Tnni3-Y113) pTyr
is downregulated in both HCM models but only reached
statistical signiﬁcance in R403Q-αMyHC Tg mice hearts. Titin
phosphorylation (TtnY1881, Y1901, and Y33864) was signiﬁcantly downregulated in the latter model.
We used MATLAB, a custom-made PhoshoEnrichment
software (M. Ayati), which integrates the Molecular Signatures
Database (MsigDB)23 and a novel database of PTMs sitespeciﬁc phosphorylation signatures of kinases, perturbations,
and signaling pathways (PTMsigDB)24. The Broad Institute
created the databases, which comprehend a well-curated
collection of annotated gene data sets and PTMs. PTMsigDB
accounts for phospho site-speciﬁc changes and their impact on
activating or inhibiting a given pathway, together with the most
common experimental systems biology perturbations. The
advantage of these bioinformatics tools is to assess the statistical
signiﬁcance of each pathway and perturbation (gene-level and
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Fig. 2 Workﬂow for global whole heart TMT phospho-tyrosine proteomics proﬁling. a Ventricular tissues were rinsed with PBS and subjected to Heat
Stabilization using a T1 Tissue Stabilizor to maximize phosphorylation preservation, then snap-frozen in liquid nitrogen and stored at −80 °C until further
use. b Ntg, TgErbB2, and R403Q-αMyHC mice hearts (n = 5 per group) were processed in parallel to obtain whole heart lysates; 30 mg of protein lysates
were used from each mouse heart for in-solution trypsin digestion, a total of 150 mg of trypsinized protein per genotype were C18 desalted and lyophilized
at −20 °C for three days. c A total of 150 mg of tryptic peptides (pooled material from 5 hearts per group) were enriched for pTyrosine using
immunoafﬁnity precipitation (Protein Agarose Beads + 300 micrograms of mAb Anti-pTyr) and desalted on C18 stage tips. d RP-HPLC ESI (electrospray
ionization) MS/MS was performed on an LTQ Orbitrap Elite (Thermo Scientiﬁc) for a 120 min on a linear acetonitrile gradient (4−40%). Raw data were
searched with Mascot 2.3, and label-free quantiﬁcation with MS1 extracted ion chromatograms were performed using MaxQuant. This approach was
repeated three times with samples from all three groups running parallel; 15 hearts per genotype in three technical replicates. e A fraction of the ﬂowthrough of pTyr enrichment was used for a 9-plexTMT; three replicates of each genotype (Ntg, TgErbB2, and R403Q-αMyHC) were pooled, fractionated in
RPLC for full proteome quantiﬁcation, f Data from pTyrosine and Full Proteome were processed in a similar way, pTyrosine signals were normalized to
matched total protein expression to normalize data. Analyses are detailed in the text and supplemental data. g Shows the overlap of phosphorylated
proteins found in the three groups, whereas h shows the overlapping tyrosine-phosphorylated peptides among the three groups.
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site level) using a hypergeometric test. Here, the number of
identiﬁed phosphosites and genes is used as the population for
the hypergeometric model parameter instead of all
known genes.
A pathway enrichment analysis was performed on signiﬁcant
genes/sites using a gene-protein level with MSigDB. TgErbB2

ARTICLE

mice’s signiﬁcant pathways are arrhythmogenic right ventricular
cardiomyopathy (ARVC), HCM, DCM, and Integrin AlphaIIB
Beta3 Signaling (Fig. 3f). R403Q-αMyHC Tg most signiﬁcant
pathways are the angiopoietin receptor pathway, ErbB signaling
pathway, growth hormone receptor signaling, and chemokine
signaling pathway (Fig. 3f).
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Fig. 3 PTMSigDB reveals common pTyr signatures of cardiac proteome in HCM. a Unsupervised PCA of the full cardiac Proteome of Non-transgenic,
TgErbB2, and R403Q-αMyHC mice show distinct segregation of the experimental groups. The groups segregate along with the ﬁrst principal component
(PC #1), which accounts for 46% of the total correlation in the expression of Full Proteome (normalized, mean = 0, variance = 1). b Unsupervised PCA of
the pTyrosine peptides signal normalized to full proteome expression. The groups also segregate along with the ﬁrst principal component (PC #1),
accounting for 52.2% of the total correlation. c A heatmap was used to visualize the unsupervised hierarchical clustering of pTyrosine peptides normalized
to full proteome expression with a p-value < 0.05 by ANOVA. Overrepresented (yellow) and underrepresented (Blue). d Volcano plot showing the Log2
fold-change and –Log10 p-value of each pTyr peptide in the pairwise comparison of Ntg and TgErbB2. The data points highlighted in red show a
signiﬁcantly lower intensity, whereas the data in green show signiﬁcantly higher intensity. The signiﬁcant sites were magniﬁed in the ﬁgure (dotted
squares) to label some peptide sites. Magenta data points match genes signiﬁcantly associated with MsigDB disease pathways. Cyan data point did not
reach statistical signiﬁcance although point to EGFR1 pathway. e Volcano plot showing the Log2 fold-change and –Log10 p-value of each pTyr peptide in the
pairwise comparison of Ntg and R403Q-αMyHC. Red and green data points were color-coded as above. With a similar magniﬁcation as above, cyan data
points show a signiﬁcant association to EGFR1 Pathway by PTMsigDB. f Molecular Signature DB (MSigDB) and Molecular PTMs Signature DB (PTMsigDB)
of Global pTyr data identiﬁed pathways that were signiﬁcantly altered.

Both Tg animal models showed a remarkable alteration in
plakophilin-2 (PKP2) pTyr at the site Y119, although in TgErbB2
hearts, it was down-regulated, and in R403Q-αMyHC Tg hearts,
it was upregulated (Fig. 3e). MsigDB analysis of global whole
heart TMT ﬂow through the entire proteome is displayed in
Supplementary Data 3. PKP2 is a critical component of the
myocardium’s desmosomes. Mutations in this gene are associated
with arrhythmogenic cardiomyopathy25–27. Therefore, disturbed
phosphorylation of Plakophilin-2 could have a functional impact.
In comparison, the PTMsigDB revealed that pathway analysis
at the phosphorylated site-speciﬁc level did not reach statistical
signiﬁcance for the EGFR1 Pathway in TgErbB2 mice; only two
site-speciﬁc phosphosites matched the EGFR1 pathway; they are
highlighted in cyan color at the Volcano plot (Fig. 3d) and
PTMsigDB table (Fig. 3f). Intriguingly, in R403Q-αMyHC mice,
the same pathway was statistically signiﬁcant; see the ten sitespeciﬁc changes that matched the EGFR1 pathway (p = 0.001)
represented in the volcano plot as cyan data points (Fig. 3e) and
PTMsigDB table (Fig. 3f). These data show the utility of
phosphorylation site-speciﬁc databases to narrow the search for
a biologically relevant pathway on phosphoproteomics data sets,
particularly in understudied phosphorylation events such as pTyr
with small data sets to date.
TMT-labeled quantitative proteomics of TgErbB2 conﬁrms
cardiac sarcomere tyrosine phosphoproteome dysregulation.
We used a TMT quantitative labeling proteomics to gain more
speciﬁc insight into the myoﬁlament pTyr changes. More speciﬁcally, we hypothesized that myoﬁlament enrichment would
enhance the number of site-identiﬁcation in myoﬁlament proteins, especially those with low abundance phospho-tyrosine
modiﬁcations that may have been missed using the global
approach. To this end, we utilized myoﬁlaments freshly isolated
from Ntg and TgErbB2 mice, as described in “Methods”28, with
minor modiﬁcations. We used three hearts per genotype to
characterize the myoﬁlament pTyr proteome (Fig. 4a, b), as
described for the heart failure phosphoproteome20. Brieﬂy, we
performed a large-scale 6-plex TMT experiment where most of
TMT-labeled peptides were enriched for pTyr (Fig. 4c). We
adopted a workﬂow similar to whole heart TMT phosphotyrosine proteomics for further statistical data analysis (Fig. 4d).
The peptides identiﬁed with single spectra were removed, which
led to 24,727 PSM. After median sweep normalization, 1116
peptides corresponded to 1,092 proteins. See Supplementary
Fig. 4a, b for spectral intensity distribution before and after
normalization (Supplementary Fig. 4c, d). For the pTyr proteome,
4391 PSM were collected and followed the same quality control
curation of the entire proteome to remove missing data and
unique spectra, which led to 3064 PSM. Raw data of pTyr proteome spectral intensity distribution are shown before
6

normalization (Supplementary Fig. 5a, b) and after normalization
(Supplementary Fig. 5c, d) and PCA (Fig. 5b). After median
sweep normalization, 832 peptides corresponded to 184 different
proteins. Speciﬁc pTyr for 146 peptides was quantiﬁed because
they had corresponding peptides from the full proteome’s
expression data.
The ﬁrst step of the analysis uses unsupervised PCA and
hierarchical clustering. PCA analysis showed the correlation
between members in the same group (Fig. 5a–c), full proteome,
pTyr proteome, and normalized pTyr proteome segregate well
along PC1, showing a correlation of expression of 57.6%, 82.4%,
and 62.1%, respectively. Heatmaps of hierarchically clustered
expression helped visualize how TgErbB2 cardiac overexpression
largely inﬂuenced the genotype clustering. Both patterns, proteins
from the whole proteome (Fig. 5d) and the normalized intensity
of pTyr proteome (Fig. 5e), suggested a mirrored remodeling (377
proteins for the entire proteome and 51 pTyr peptides had a
p < 0.05 by LIMMA moderated 2-sample t-test comparison).
The full proteome detected 1116 peptides which corresponded
to 1092 proteins. A comparison of the Log2 fold-change (FC) of
Ntg/TgErbB2 showed 377 proteins with statistically signiﬁcant
differences (Log2 FC > 1 and p-value < 0.05). Like whole global
heart TMT phospho-tyrosine normalized to full proteome data,
the statistically signiﬁcant protein expression changes were
subjected to MSigDB for pathway analysis. The results are shown
in Supplementary Data 4.
We used 146 phospho-sites corresponding to 50 proteins to
analyze the pTyr proteome phosphorylation or normalized pTyr
proteome. The TgErbB2 mice showed signiﬁcant changes in 21
pTyr sites (Fig. 5g) corresponding to 15 proteins. A substantial
increase of pTyr was detected on MLC1-Y82, Y139, Myh6-Y1310,
α-Tm-Y261, Actin-Y168, MyBP-C-Y544, and Actinin2-Y200,
among other proteins. The MsigDB pathway analysis yielded
results similar to the global TMT phospho-tyrosine approach
on whole hearts (Fig. 3). TgErbB2 sarcomere pTyr data also
show that the most signiﬁcant pathways are DCM, and HCM
(Fig. 5g, h). Interestingly, when normalized to total ErbB2, the
ErbB2-Y1006 phosphorylation levels decrease. On the other hand,
the PTMsigDB pathways analysis did not match any pathways
because many sites are new and not reported in the PTMsigDB
database.
Our data show that the enrichment of sarcomere proteins
detected more myoﬁlament pTyr peptides that were missed in the
global approach of whole heart lysates. However, the total
number of tyrosine-phosphorylated peptides and corresponding
proteins was lower.
KSEA implicated downregulation of MAPK in TgErbB2 and
upregulation of EGFR in R403Q-αMyHCTg. KSEA was used to
characterize genotype-induced signaling changes by estimating
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Fig. 4 Workﬂow for cardiac sarcomere pTyr identiﬁcation of normal and TgErbB2 hypertrophic myoﬁlaments by TMT quantitative proteomics.
a Myoﬁlament from Ntg (n = 3) and ErbB2 (n = 3) transgenic mice hearts were freshly isolated on ice-cold buffers containing Proteinase and Phosphatase
Inhibitors Cocktails (Roche). b All material was resuspended in TEAB, then reduced and alkylated. Tryptic peptides were desalted and labeled with 6-plex
isobaric tandem mass tags (TMT). c The digested and labeled peptides were pooled and desalted with C18 SEP-PAK. The enrichment for phosphotyrosine
was performed with PTMScan Phospho-Tyrosine Rabbit mAb (P-Tyr-1000) kit (Cell Signaling Technology). The eluted peptide samples were desalted
using C18 STAGE tips d Easy-nanoLC 1200 nanoﬂow liquid chromatography system coupled to Orbitrap Fusion Lumos Tribrid.

the kinase’s relative activity in TgErbB2 and R403Q-αMyHC mice
using the global whole heart pTyr TMT and TMT quantitative
sarcomere pTyrosine proteomics data, using their respective Ntg
groups as a reference. KSEA29 is a method that infers the kinases’
differential activity based on the differential phosphorylation of
its substrates and computes scores that reﬂect the directional
change in each kinase’s activity. This method assumes that the
differential activity of kinases is correlated with phosphorylation
changes in its substrates. A positive score corresponds to a kinase
with phosphorylated substrates in Tg mice relative to Ntg control.
Likewise, a negative score is a hypophosphorylation in Tg relative
to their Ntg control. The kinase-substrate interaction data was
downloaded from the PhosphoSitePlus30 website. Next, the KSEA
method was applied to all the pTyr sites identiﬁed in these
experiments. We identiﬁed 34 phosphosites that have associated
kinases reported on PhosphoSitePlus. However, 49 unique kinases were scored in the combined data sets. A KSEA heatmap
inferred clusters of kinases downregulated (blue color scale) or
upregulated (red color scale) is shown in Fig. 6a. TgErbB2 mice
displayed signiﬁcant downregulation of MAP2K4, MAP3K6,
MAP3K5, MAP2K3, and MAP2K6, and marked upregulation of
EPHA4. On the other hand, R403Q-αMyHC Tg showcased a
substantial downregulation of GSK3B (see highlighted blue rectangle in Fig. 6a). R403Q-αMyHC Tg displayed a larger cluster of
signiﬁcantly upregulated kinases (see highlighted red rectangle in
Fig. 6a).
Conventional pathway analysis can miss protein groups
because pathway algorithms are predeﬁned and rigid. A
protein–protein interaction (PPI) network approach might better
capture signaling responses in these models that are not typically
detected by pathway analysis. To do so, MoBaS Analysis22,31 was
employed to identify densely connected subnetworks that are
related and might exhibit differential phosphorylation in Tg
models. Several modules were identiﬁed, and we focused on the
top two statistically signiﬁcant PPI modules from the global
whole heart TMT ﬂow through dataset; for interpretation

purposes, they were designated as Module 1 and Module 2. The
substrates of modules 1 and 2 are illustrated in Fig. 6b, d,
respectively.
Interestingly, PTMsigDB site-level molecular signature analysis
showed that module 1 contained signiﬁcant site-speciﬁc modiﬁcations for the EGFR1 pathway. In addition, using MSigDB
Gene-Protein Level analysis, several pathways, such as the ErbB
signaling, PDGFRA, and focal adhesion pathways, showed
statistical signiﬁcance. KSEA of module 1 protein-protein
network highlights signiﬁcant activation of AURKB (aurora
kinase B) and CSNK2A1 (Fig. 6c).
Similarly, PTMSigDB analysis for module 2 conﬁrmed the
involvement of EGFR1 Pathway while MsigDB detected actin
cytoskeleton, ErbB signaling, and focal adhesion pathways. KSEA
of module 2 protein-protein network highlights signiﬁcant
activation of SRC, MAP2K1, HCK, LCK, SYK, JAK3, JAK2,
FYN, PTK6, and ABL1 in R403Q-αMyHC mice (Fig. 6e). These
data conﬁrm that MoBAS identiﬁed functionally relevant
modules of PPI among identiﬁed pTyr peptides, and PTMsigDB
pointed to EFGR1 Pathway as a common pathway for HCM from
two unrelated mouse models.
Tyrphostin AG-825 administration decreased cardiomyocyte
disarray in the TgErbB2 mouse model. TgErbB2 mouse hearts
develop a concentric type of HCM. This alteration rapidly progresses to pathologic HCM, showing features such as ﬁbrosis,
cardiomyocyte disarray, perturbed Ca2+ handling, arrhythmias,
and sudden death16. On these grounds, we hypothesized that
counteracting the activity of cardiac ErbB2 overexpression
pharmacologically, a tyrosine kinase receptor, using AG-825 (an
ErbB2 inhibitor), would halt the progression of the histopathological phenotype. To that end, TgErbB2 mice (ages 6–9 months)
with established HCM and Ntg controls were treated with AG825 or DMSO vehicle for two weeks, subcutaneously twice daily
at a dose of 1 mg/Kg16. Next, myocardial ﬁbrosis was evaluated by
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Masson’s trichrome staining. Untreated TgErbB2 mice developed
variable amounts of ﬁbrosis of the left ventricle (Fig. 7a, b);
however, TgErbB2 treated mice displayed less ﬁbrosis (Fig. 7b). In
contrast, cardiac histology was not affected by AG-825 Treatment
in Ntg mice. We used CytoSpectre32, a web graphic user interphase, to characterize the effects of AG-825 on cardiomyocyte
disarray; this interphase determines the local orientation of
structures, including cardiac myocytes, across histological
8
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sections, similar to the analysis described previously by the
Seidman’s laboratory33. Randomly chosen regions of interest are
depicted in Fig. 7a, and increase the magniﬁcation of microphotographs from 5X to 40X (Fig. 7b). The myocyte orientations
angle variance was evaluated, referred to as Circular Variance and
means orientation angles variance. Ntg treated with the vehicle
(Fig. 7c) compared to Ntg AG-825 treated (Fig. 7c) was not
signiﬁcantly different (Fig. 7d), as already described33. In
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Fig. 5 TgErbB2 cardiac sarcomere pTyr proteome remodeling. a Full Proteome was labeled with TMT, and the logged and summarized protein signal
intensities indicate that experimental groups segregate along with the ﬁrst principal component (PC #1), which accounts for 53.9% of the total correlation
in the expression proteome (normalized, mean = 0, variance = 1). b PCA of the phospho-Tyr Proteome reveals a similar trend, and the groups segregate
along the PC#1, which accounts for 47.2% of the correlation. c Signal intensities of the phospho-Tyr proteome were normalized to Full Proteome protein
expression and analyzed by principal component analysis. The distinctive signature of pTyr is still apparent by PC#1 and accounts for 57% of the
correlation. d A heatmap was used to visualize the unsupervised hierarchical correlation clustering of protein expression and e pTyr Proteome expression
with p < 0.05 by LIMMA moderated 2-samples t-test comparison of TgErbB2 and Ntg group. f Volcano plot showing the Log2 fold-change and –Log10 pvalue of each pTyr peptide in the pairwise comparison of Ntg and TgErbB2. The data points in red showed a signiﬁcantly lower intensity, whereas the data
points in green showed a signiﬁcantly higher intensity. For clarity of presentation, only some peptides were highlighted. g Molecular Signature DataBase
(MSigDB) conﬁrmed targets and the involvement of Dilated and HCM KEEG Pathways also found on TgErbB2 mice in Fig. 3.

contrast, TgErbB2 mice cardiomyocytes treated with the vehicle
displayed an orientation angle variance that was substantially
different from Ntg-Vehicle control; see the heterogeneous and
broader shape of the orientation plot in Fig. 7c. Surprisingly,
cardiomyocytes from TgErbB2 mice AG-825 treated displayed
signiﬁcantly less disarray, as demonstrated by the signiﬁcant
return of circular variance and shape of the plot to Ntg- Vehicle
or AG-825 treated controls (Fig. 7e, p = 0.0014 by One-way
ANOVA). This analysis suggests that cardiomyocytes from
TgErbB2 mice AG-825 treated displayed signiﬁcantly less myocyte disarray, as indicated by reduced circular variance.
Next, we evaluated the direct in vivo impact of ErbB2
inhibition by AG-825 on contractility, echocardiograms, and
tissue-doppler imaging to assess diastolic function. These studies
were performed on conscious (non-anesthetized) mice, at baseline and after two weeks of Treatment. We used a Vevo 2100
High-Resolution Imaging System with a 40 MHz transducer
(VisualSonics®, Toronto). The data were subsequently analyzed
with an Advanced Cardiovascular Package Software. The
parameters studied were chamber dimensions, fractional shortening, ejection fraction, and tissue Doppler velocity dynamics.
Left ventricle functional data obtained by parasternal short-axis
echocardiographic imaging determined no signiﬁcant change in
the mean fractional shortening over time in TgErbB2 mice treated
with vehicle solution compared with the Ntg (Fig. 7f). Similarly,
TgErbB2 mice treated with AG-825 did not display signiﬁcant
changes in contractile function over time compared to Ntg AG825 treated (Fig. 7f). Tissue Doppler imaging detected no
signiﬁcant differences in diastolic function; see complete
Echocardiography data in Supplementary Data 6. These data
suggest that ErbB2 pharmacological inhibition halted or reversed
pathological remodeling by reducing the ﬁbrotic response and
restoring cardiomyocyte alignment. Yet, this response was not
paralleled by in vivo preservation of LV contractile function in
TgErbB2 mice.
Extensive phosphoproteomics validate EGFR1 pathway activation on cardiac hypertrophy of TgErbB2 that is inhibited by
tyrosine kinase inhibitor (AG-825). We revisited the phosphoproteomics of TgErbB2 and NTg to validate bioinformatic ﬁndings of KSEA and to study the impact of the tyrosine kinase
inhibitor AG-825 on the proteome. We used a TMT 13-plex
labeling approach to compare the whole heart phosphorylation
proﬁle of Ntg and TgErbB2 mice treated with vehicle or AG-825
(ErbB2 inhibitor). Brieﬂy, a TMT 13-plex was performed as follows; Ntg-Vehicle (n = 3), Ntg-AG-825 treatment (n = 3),
TgErbB2-Vehicle (n = 3) and TgErbB2-AG-825 treatment
(n = 4). Whole heart protein lysates were isolated from thermally
stabilized hearts and processed as described in Fig. 2 and
“Material and methods”. Most of the material was used to enrich
pS/pT/pY peptides, and a small portion is labeled to quantify full
proteome with TMT. As described in the previous experiment in
Fig. 2, the intensity of pS/pT/pY peptides is normalized to the

intensity of full proteome TMT signals. A total of 6614 proteins,
4732 phosphorylated serine and threonine peptides, and 346 pTyr
peptides were quantiﬁed by TMT reporter ions. The full dataset is
available in Supplementary Data 7.
Heatmaps of hierarchically clustered up- or down-regulated
normalized serine/threonine phosphorylated, or tyrosinephosphorylated peptides intensity conﬁrm the inﬂuence of the
genotype on all phosphoproteome remodeling, serine and
threonine phosphorylation (Fig. 8a) and pTyr (Fig. 8b). We
directly interrogated data with MSigDB and PTMSigDB to
compare Ntg with TgErbB2 mice. As anticipated, we conﬁrmed
the involvement of EGFR1 Pathway by PTMSigDB in TgErbB2
mice cardiac hypertrophy treated with vehicle (Fig. 8c, d) or
AG-825 (Fig. 8e, f). Also, we conﬁrmed the involvement of focal
adhesion and extracellular matrix pathways by MSigDB in
vehicle-treated mice and dilated cardiomyopathy, HCM, and
arrhythmogenic right ventricle cardiomyopathy (ARCV) in AG825 treated mice. However, AG-825 Treatment for 14 days had
a subtle effect in TgErbB2 mice that was not evident by MsigDB
or PTMsigDB. Since we included all phosphoproteome, we
estimated kinase activity in serine and threonine phosphorylation peptide. The top upregulated and downregulated kinases
were identiﬁed using KSEA, and the result is presented in
Fig. 8g. The complete KSEA and pathway analysis are available
in Supplementary Data 5 and Supplementary Data 7. We
compared the activity of kinases in AG-825 treated animals
relative to their control (vehicle treatment). We identiﬁed a
small cluster of kinases signiﬁcantly inhibited or downregulated by AG-825 Treatment and not by vehicle treatment
(See highlighted red rectangle in Fig. 8g). To get more insights
on the functional impact from a system biology point of view,
we explored the relation of these kinases using The Signaling
Network Open Resource (Signor 2.0) visualization software34.
Figure 8h shows that most of these kinases are downstream of
EGFR, highlighted in blue dotted circles. Altogether, our data
indicate that EGFR1 is central to hypertrophy of TgErbB2 and
that AG-825 Treatment inhibits ErbB2 and EGFR; therefore, a
signiﬁcant subset of targets downstream of EGFR signaling
cascade are affected.
Discussion
The present study demonstrates that the pTyr proteome of the
heart is altered in proteins related to cardiomyopathies, serine/
threonine, and tyrosine kinases in two pathogenetically-unrelated
models of hypertrophy cardiomyopathy (HCM), namely cardiacspeciﬁc overexpression of ErbB2 and allelic expression of R403QαMyHC. In addition, the serine/threonine phosphoproteome of
the heart is also altered in the TgErbB2 mouse model cardiac
hypertrophy. Altogether our data point that EGFR pathway
activation is centrally involved in cardiac hypertrophy that rises
from two very different mouse models.
Heart failure contractile dysfunction is, in part, due to
myoﬁlament Ca2+ desensitization. Altered serine/threonine
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phosphorylation of the cardiac sarcomere and reduced myoﬁlament Ca2+ sensitivity are features of human and experimental
models of heart failure and play a role in the pathophysiology of
HCM and DCM7,35,36. We have previously identiﬁed pTyr in
human cardiac Troponin I Y26 that was downregulated in human
heart failure and DCM14. However, no studies have yet addressed
10

the impact of global dysregulated cardiac pTyr in the pathogenesis of cardiac disease.
Here, we show evidence that in TgErbB2 mice’s heart, tyrosine
phosphoproteome is altered in a differential fashion, upregulation, and downregulation of tyrosine phosphopeptides. MsigDB
pathway analysis demonstrated the involvement of ARVC, HCM,
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Fig. 6 KSEA & MoBaS analysis. a KSEA on whole hearts pTyr enrichment and TMT pTyr Myoﬁlament enrichment data. Heat maps report KSEA results
according to normalized scores (i.e., TgErbB2/Ntg, R403Q-αMyHC/Ntg, etc.). Only kinases shared between data sets are included, therefore present in Tg
and Ntg. Asterisks indicate the statistical signiﬁcance of p < 0.05. Red represents a positive score, and blue is a negative score. Red rectangle highlights
groups of activated kinases clustered together and are predominant in R403Q-αMyHC, whereas the blue rectangle highlights suppressed kinases that
clustered and are predominant on TgErbB2 whole hearts. b MoBaS identiﬁed a tightly interconnected subnetwork involved in growth factors signaling
(ERBB, PDGFRA, and EGFR1). Represented by the top-scoring PPI subnetwork called Module 1 was identiﬁed on TgErbB2 whole heart pTyr enrichment and
compared to R403Q-αMyHC. c KSEA on Module 1 group of substrates, MsigDB and PTMsigDB. d Second top-scoring PPI subnetwork called Module 2 was
identiﬁed on R403Q-αMyHC whole heart pTyr enrichment and compared to TgErbB2. e KSEA on Module 2 group of substrates show activated kinases in
R403Q-αMyHC. Results from PTMsigDB and MSigDB analysis identiﬁed EGFR1, Actin cytoskeleton, ERBB and Focal Adhesion signaling. Each node is a
phosphoprotein represented by its most signiﬁcant peptide on PPI modules. Node color is based on Log2 fold-change relative to NTG. The scale is noted by
FC and a bar colored from blue to red.

DCM, and integrin alphaIIB beta3 signaling in TgErbB2 mice
hearts. Most of the sarcomere proteins had signiﬁcant downregulation of pTyr, such as Myh7-Y386, Y410, Y1375, Myh6Y1349, and Ttn-Y2118, Y21190, except for Ttn-Y31324 that was
upregulated. The directional change of pTyr in these sarcomere
proteins is downregulation, just like it was reported for human
cTnI Y26 in heart failure and DCM. Very little is known about
the role of pTyr of sarcomere proteins. In fact, only one group37
has examined the potential tyrosine kinases that phosphorylate
cTnI. They demonstrated in vitro that c-Src and another Src
kinases family member, Lyn, phosphorylates the cTnIY26,
reporting
phosphorylation
and
pseudo-phosphorylation
mimicking at this site reduced myoﬁlament Ca2+ sensitivity, as
evidenced by the altered force-calcium response of the myoﬁlaments. Noteworthy, cTnI Y113 phosphorylation, a novel discovered site, was downregulated in R403Q-αMyHC mice. We also
demonstrated signiﬁcant downregulation of pTyr in Ttn-Y1881,
Y1902, and Y33864. Contrary to TgErbB2 mice, Myh7-Y410 was
upregulated in R403Q-αMyHC mice. pTyr at Myh7-410 is near
R403Q αMyHC and could have a functional impact since it is in
the motor domain head of αMyHC. The site-speciﬁc implications
of these changes are worthy of further study; however, it is
beyond the scope of the present work. Interestingly, in the
R403Q-αMyHC hearts, pTyr proteome is also altered differently.
However, in R403Q-αMyHC mice, more phosphotyrosine peptides reached statistical signiﬁcance. Unlike TgErbB2, the MsigDB
pathway analysis demonstrated that R403Q-αMyHC mice had
alterations in tyrosine kinase receptor pathways, angiopoietin
receptor, ErbB, and growth hormone receptor signaling. Whereas
PTMsigDB revealed the alteration of the EGFR1 Pathway and
squamous cell carcinoma. We reasoned that overexpression of a
receptor tyrosine kinase in TgErbB2 mice hearts would result in a
more signiﬁcant alteration of pTyr proteome. However, the data
suggest that a single sarcomere point mutation, as in the case of
R403Q-αMyHC mice, is incisive enough to alter the cardiac pTyr
proteome signiﬁcantly. Top-down proteomics38 demonstrated
that consistent alterations of cTnI, ENH2, and other Z-disk
protein phosphorylation in HCM myocardium correlated better
with the phenotype, regardless of the single sarcomere point
disease-causing mutation. The mechanisms that a pathogenic
mutation in the myosin heavy chain (R403Q-αMyHC) may affect
pTyr regulation are unknown and warrant further investigation.
Global pTyr dysregulation in the TgErbB2 mouse model is
essential because it connects pronounced cardiac hypertrophy,
sarcomere dysfunction, and abnormal calcium handling16 with
alterations in tyrosine kinase pathways. On the other hand,
pharmacological inhibition of ErbB2 (HER2/neu) with the inhibitor lapatinib in breast cancer patients treated with doxorubicin
increases the risk of developing heart failure compared to patients
treated with doxorubicin alone39. It suggests that maintaining
pTyr homeostasis may be necessary for regulating cardiomyocyte
function and homeostasis.

A wide variety of other functionally relevant targets were
identiﬁed in this study with pTyr, from sarcomere proteins to zdisk, intermediate ﬁlaments (such as desmin), desmosome components, focal adhesion, and adherence junction proteins, membrane receptors, kinases, and phosphatases. For instance, pTyr in
several z-disk-associated proteins was noted (for a complete list,
see Supplementary Data 2, 3, and 6). Z-disk proteins are crucial
for muscle contraction and mechanical stress, growth, and
metabolic signaling40. Also, the alteration in the phosphorylation
levels of the desmosome key component Plakophilin-2 protein
(Pkp2) peptide Pkp2-Y119 was noted in both mouse models,
upregulation in R403Q-αMyHC Tg and downregulation in
TgErbB2. The functional effect of up- or downregulation of Pkp2Y119 phosphorylation is not known. However, Pkp2 homozygous
deletion disrupts heart architecture and is lethal in the embryo41.
In the heart, Pkp2 is required to assemble the desmosome and the
PKC activity42. Autosomal dominant mutations in this gene are
responsible for 25 to 50% of ARVC. Interestingly, TgErbB2 mice
have increased susceptibility to arrhythmias and myoﬁbrillar
disarray16, similar to patients with myosin mutations and HCM.
Pkp-Y119 phosphorylation changes could impact the phenotype.
The EGFR1 (ErbB1) pathway plays a central role in cardiac
hypertrophy in both Tg models. EGFR pharmacological inhibition, using AG-1478, protects against Angiotensin II-induced
cardiac hypertrophy in vitro and in vivo43. The concentric
hypertrophy associated with ErbB2 cardiac-speciﬁc overexpression can be reversed by early administration of Lapatinib,
which inhibits EGFR receptor tyrosine kinase12 in addition to
ErbB2. In this study, the ErbB2 receptor’s pharmacological
blockage by AG-825 in TgErbB2 adult mice reduced myocyte
disarray but did not preserve cardiac function or alter cardiac
hypertrophy. We think that the lack of response is related to the
age of mice at the time of administration: in the current study, we
used adult mice, whereas pups have been used in previous
studies15. We also evaluated the cardiac serine/threonine and
pTyr proteome in TgErbB2 after vehicle or AG-825 Treatment.
We found global alterations in the phosphoproteome (Fig. 8) that
conﬁrmed the involvement of the EGFR pathway. In addition, we
conﬁrmed the alterations in focal adhesion, extracellular matrix,
DCM, HCM, and ARCV pathways. We used KSEA to pair the
ﬁndings with a subset of activated kinases and narrow it down to
the top 40 most representative serine/threonine and tyrosine
kinases detected in the cardiac proteome of Ntg and TgErbB2
mice. AG-825 Treatment could inhibit or signiﬁcantly reduce the
activation of 14 kinases corresponding to the EGFR pathway
(Fig. 8g, h), suggesting that AG-825 Treatment was effective and
speciﬁc. Altogether these ﬁndings indicate that alterations of
cardiac proteome span to serine/threonine and pTyr, conﬁrming
the involvement of the above-described pathways. In addition,
these data suggest that AG-825 treatment-induced changes in the
phosphoproteome correlated with an improvement in cardiac
myocyte disarray.
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Fig. 7 Tyrosine kinase receptor inhibitor AG-825 reduces cardiac myocyte disarray without effects on contractile function in TgErbB2 mice.
a Masson’s trichrome stained sections (5X) from vehicle-treated Ntg and AG-825–treated Ntg and vehicle-treated TgErbB2 and AG-825-treated TgErbB2
mice, yellow arrowheads point to ﬁbrotic areas. Scale bar 1 mm. b Masson’s trichrome stained sections (40X) from representative regions of interest show
increased Fibrosis in TgErbB2 mice myocardium, that ﬁbrosis improved after 2 weeks of AG-825 Treatment. The same areas were used to determine the
level of cardiac myocyte disarray, which was achieved by analyzing cell orientation using CytoSpectre Software from Vehicle and AG-825 treated Ntg and
TgErbB2 mouse heart sections (scale bar 50 μm). c Plots of the distribution of cardiac cells orientation angles. Note how Ntg angles are homogeneous and
did not change in the group treated with AG-825. In contrast, Tg treated with vehicle showed less homogenous and different orientation angles, conﬁrming
cardiomyocyte disarray. AG-825 Treatment reduces cardiomyocyte disarray, and the orientation plot is similar to the AG-825 treated NTG group. d Mean
orientation angle of cardiac myocytes, and e Circular variance, another measure of isotropy, in Ntg and TgErbB2 mice with and without AG-825 treatment
(n = 5 animals per condition). Graph bars are expressed as mean ± s.e.m.; a one-way ANOVA test was performed for statistical comparisons showing a
signiﬁcant improvement in TgErbB2 mice treated with AG-825 (p-value < 0.0014). f Cardiac echocardiography from the four groups shows that AG-825
Treatment for 14 days did not modify the contractile function, estimated as % Fraction Shortening.

The KSEA implicated a marked downregulation of members of
the canonical MAPK pathway downstream of k-Ras in TgErbB2
mice. Conversely, in R403Q-αMyHC mice, we observed an
upregulation of focal adhesion and PDGFR-beta signaling pathways (SRC, LYN, LCK, JAK2, INSR, MAPK1, and HCK). More
importantly, modularity-base scoring (MoBas) analysis identiﬁed
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protein-protein interaction subnetworks enriched in ErbB,
PDGFRA, and focal adhesion pathways and activation of aurora
kinase B and CSNKA1. These data indicate that many targets
overlap in both transgenic models of cardiac hypertrophy.
Although there are marked differences in the upstream regulators
of ErbB2 and myosin heavy chain, many downstream effector
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Treatment
Vehicle
AG-825
Genes in Pathway

P-value

Dilated Cardiomyopathy

Pathway (sigDB)

LMNA, MYH6, MYH7, MYL2, TTN

0.001

Hypertrophic Cardiomyopathy

LMNA, MYH6, MYH7, MYL2, TTN

0.001

Pathway (PTMsigDB)

Genes in Pathway

P-value

Prolacn Pathway

SHC1-Y349, SHC1-Y350

0.0004

EGFR1 Pathway

SHC1-Y349, SHC1-Y350

0.05

h

Fig. 8 Comprehensive serine/threonine/tyrosine phosphoproteomics conﬁrm EGFR1 pathway involvement in TgErbB2 hypertrophy and tyrosine
kinase receptor inhibition by AG-825. a A heatmap was used to visualize the unsupervised hierarchical clustering of Ser/Thr peptides, and b pTyrosine
peptides normalized to full proteome expression with p-value < 0.05 by ANOVA. Overrepresented (yellow) and underrepresented (Blue). c Volcano plots
showing the Log2 fold-change and –Log10 p-value of each pSer/pThr peptide and d pTyr peptides in the pairwise comparison of Ntg and TgErbB2 after two
weeks of Vehicle Treatment. e Volcano plots showing the Log2 fold-change and –Log10 p-value of each pSer/pThr peptide and f pTyr peptides in the
pairwise comparison of Ntg and TgErbB2 after two weeks of AG-825 Treatment, (g) KSEA shows in a red rectangle the kinases signiﬁcantly inhibited by
AG-825. KSEA and Pathway Enrichment Analysis of combined Ser/Thr/Tyr phosphorylation data analysis using PTMSigDB conﬁrm that EGFR1 Pathway is
signiﬁcantly involved. h The Signaling Network Open Resource (Signor 2.0) analysis shows that nine kinases are involved in the EGFR pathway. Kinases
found in the network and also in KSEA are circled in dotted blue circles. The symbol code of the network is displayed next to the pathway.
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molecules are common and can be targeted by small-molecule
inhibitors (designed initially to treat several types of cancer) to
block cardiac hypertrophy.
The MAPK pathway is involved in the adaptive and maladaptive response that could lead to heart hypertrophy (for
review44). The RAS-RAF-MEK-ERK signaling pathway is an
attractive target for oncology therapeutic intervention. Several
selective RAF and MEK small-molecule inhibitors have been
tested in clinical trials45. The present study found increased
phosphorylation at MAPK1-Y185, which activates the kinase in
R403Q-αMyHC, and MAPK1 activity directly relates to heart
hypertrophy46. The c-Src, the central kinase from its family, could
be one of the potential regulators for the pTyr proteome changes
observed in R403Q-αMyHC because it phosphorylates the EGFR
receptor upstream and phosphorylates Stat, among other targets,
downstream. c-Src affects the response to mechanical cardiomyocyte stretching by triggering a cascade of intracellular signaling in cardiomyocytes towards a hypertrophic response47,48.
Also, c-Src phosphorylates PXN-Y11849, and this site had a 25fold increase in phosphorylation in R403Q-αMyHC mice. Interestingly, c-Src mediates the activation of MAPK1 and MAPK3 in
response to pressure-overload47. Notably, a previous study has
shown that pressure-overload-induced cardiac hypertrophy is
exacerbated in R403-αMyHC Tg mice50, suggesting that the
mechanism by which R403-αMyHC mutation produces heart
hypertrophy is by sensitizing cells to pressure-overload-induced
signaling via c-Src.
R403Q-αMyHC mice displayed enhanced JAK2, STAT5A,
and STAT5B phosphorylation in the activation sites (Y570,
Y694, and Y699, respectively), which indicates not only activation of MAPK signaling but also activation of JAK-STAT
signaling. Jak-Stat Signaling: IL-6 pathway is activated in
response to the IL-6 family of cytokines (IL-6, cardiotrophin 1,
and leukemia inhibitor factor), cross-talks with the EGFR
pathway, and is involved in cardiac hypertrophy. This pathway
has cardioprotective effects, but chronic activation may lead to
heart hypertrophy (reviewed in ref. 44). Vakrou and colleagues
performed a pathway analysis on miRNA proﬁles of R403QαMyHC. These authors found similarities with the ﬁndings
described in this work, such as overactivation of chemokine
signaling (CXCR4), actin cytoskeleton, and cardiac hypertrophy
signaling pathways51. These results suggest an essential involvement of pTyr regulation in myoﬁlaments and other cardiac
proteins. The insight gained from these studies could inform
new therapeutic approaches in sarcomere mutation-related
HCM and potentially other conditions associated with HCM.
The studies were limited to two transgenic mouse models that
develop cardiac hypertrophy; other models of sarcomere
mutations or pressure-overload such as aortic banding could be
explored and compared. Some relevant tyrosine-phosphorylated
sites might be missed due to their low stoichiometry and
technical challenges. This problem is particularly true for
membrane-bound proteins, which are difﬁcult to evaluate in
phosphoproteomic studies.
This study reveals that altered pTyr patterns are striking in two
separate models of HCM. Moreover, despite some shared sites,
etiologically different forms of HCM may harbor speciﬁc pTyr
signatures that point EGFR pathway as central in both transgenic
models. This evidence, combined with the inhibition of a speciﬁc
receptor tyrosine kinase using tyrphostin AG-825, can reverse
cardiomyocyte disarray and rationalize approaches to manipulate
the pTyr proteome as a therapeutic approach for HCM. Furthermore, these studies indicate that tyrosine kinase inhibitors,
now used broadly in cancer therapies, may change cardiac
function by directly modifying the heart’s tyrosine kinase and
serine/threonine kinase proﬁles.
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Methods
Western blot. Whole heart lysates from Heat Stabilized Tissue were resuspended
in 1% SDS buffer, 10–15 μg were separated by SDS-PAGE, and transferred to
nitrocellulose membranes. Membranes were blocked with 5% BSA in TBS-T buffer
(20 mmol/L Tris pH 7.4, 150 mmol/L NaCl, and 0.1% Tween 20) for 1 h at room
temperature, then were incubated with primary antibody dilution 1:1000 in 1%
BSA-TBS-T; phospho-Tyrosine mouse mAb (pTyr-100, cat. No. 9411SCST), TnI
Rabbit Ab (cat. No. 4002SCTS), Src Rabbit Ab (cat. No.2108SCST), Phopsho-Src
Family (Tyr416) Rabbit mAb (D49G4, cat. No.6943T CST), GAPDH Rabbit Ab
(14C10, cat. No. 2118S CST) at 4 °C overnight. After washing them ﬁve times, the
secondary antibodies were diluted 1:10,000 in 1% BSA-TBS-T (anti-Rabbit IgGHRP linked (cat. No. 7074S CTS), Anti-Mouse m-IgGk BP-HRP (cat. No. sc516102, Santa Cruz) and incubated for 1 h at room temperature. Then, the
membranes were developed with super signal West Pico Chemiluminescent Substrate (Thermo), and the immunoreactive bands were detected by chemiluminescence with an iBright 1500 (Invitrogen). The images were obtained and analyzed
with Image J software. One-way ANOVA was used to compare groups and
determine statistical signiﬁcance.
Global whole heart TMT phospho-tyrosine proteomics
Sample preparation. All protocols were performed following the “Guide for the Use
and Care of Laboratory Animals” published by the National Institutes of Health
and the Institutional Animal Care and Use Committee’s approval. The TgErbB2
(B6SJLF1/J stain) and R403Q-αMyHC (C57/Bl6) mice were obtained from Dr. K.
Gabrielson and Dr. L. A. Leinwand, respectively16,17, to establish breeding colonies.
Male or female mice (6-9 months) were anesthetized with sodium pentobarbital IP
(75 mg/kg) or isoﬂurane (5%) overdose; the hearts were quickly dissected, followed
by thermal stabilization (Denator T1 Heat Stabilizor, Sweden) and stored at −80 °C
until analyzed. TgErbB2 and R403Q-αMyHC mice hearts (n = 5 per group) were
processed in parallel. To obtain whole heart lysates, cardiac ventricles (~200 mg)
were homogenized on ice-cold buffer: 20 mM HEPES, pH 7.6, 1 mM, 1.5 mM
sodium pyrophosphate, PhosStop, and 9 M urea at 10 μl/mg (wet weight of tissue).
The homogenate was cooled on ice, followed by brief micro-tip sonication on ice,
centrifugation at 10,000 × g for 15 min at 4 °C. The supernatant was retrieved, and
protein concentration was determined by the method of Lowry (Bio-Rad).
Trypsin digestion. Protein from heart lysates was reduced in 5 mM of dithiothreitol
(DTT) at 60 °C for 20 min and alkylated in 10 mM iodoacetamide (IDA) at room
temperature for 15 min in the dark. Each sample (30 mg per mouse, n = 5 mice per
genotype) was digested with Proteomics grade Trypsin (Promega) at a ratio of
1:200 in 2 M urea, 20 mM HEPES buffer, pH 8.0 at room temperature overnight.
The digestion was terminated with triﬂuoroacetic acid (1% TFA). Samples were
centrifuged (5 min at 1800g), and supernatants were desalted by solid-phase
extraction (SepPak C18 10cc cartridge, Waters). Elutes were lyophilized for three
days at −20 °C.
Enrichment of tyrosine phosphopeptides. A total of 150 mg of trypsinized peptides
per genotype were pooled and enriched for pTyrosine, as previously described52.
Lyophilized peptides were mixed in 1.4 ml immunoprecipitation buffer (IAP buffer
50 mM MOPS, pH 7.2, 10 mM sodium phosphate, 50 mM NaCl, pH 7.0). A stock
solution of protein agarose G beads (Santa Cruz Biotechnology) 80 μL of slurry
were conjugated with 300 μg of Phospho-Tyrosine Mouse monoclonal antibody (pTyr-100, Cell Signaling Technology). The beads-Anti-p-Tyr antibody conjugate
was transferred to the peptide’s tube and incubated with gentle rotation for 2 h at
4 °C. The beads were washed and eluted with 55 μl and 45 μl of 0.15% triﬂuoroacetic acid (TFA), respectively. The two elution yields were pooled. The
resulting peptide mixtures were puriﬁed by solid-phase extraction (stage tips C18,
Thermo Scientiﬁc). The samples were dried by vacuum centrifugation. This
approach was repeated three times with samples from all three groups run in
parallel, 15 hearts per genotype in three technical replicates. The immunoprecipitation buffer ﬂow-through was stored at −80 °C for subsequent TMT 9-plex.
According to the manufacturer’s instructions, tryptic peptides were desalted and
labeled with 9-plex isobaric TMT (Thermo Scientiﬁc). The labeling reaction was
carried out for 1 h at room temperature, followed by quenching with 100 mM
Tris.HCl (pH 8.0).
LC-MS/MS analysis. Phosphopeptides were dissolved in 10 μl of 0.1% TFA, 2%
ACN (v/v) followed by RF-HPLC-ESI-MS/MS analysis. Phosphopeptides were
separated on a C18 reversed-phase column with a linear gradient of acetonitrile
(4−40%) for 120 min and then analyzed on an LTQ-Orbitrap Elite MS (ThermoFisher Scientiﬁc) with neutro loss triggered HCD.
Peptide identiﬁcation and quantiﬁcation. Raw MS data were searched with Mascot
2.3, and label-free quantiﬁcation with MS1 extracted ion chromatograms were
performed using MaxQuant software.
TMT from ﬂow-through for total proteomics
LC-MS/MS analysis and database search. Peptides were analyzed on Orbitrap
Fusion Lumos Tribrid (Thermo Scientiﬁc) coupled with Easy-nanoLC 1200
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nanoﬂow liquid chromatography system (Thermo Scientiﬁc). The peptides from
each fraction were reconstituted in 10% formic acid and loaded on Acclaim PepMap100 Nano Trap Column (100 μm × 2 cm) (Thermo Scientiﬁc) packed with 5
μm C18 particles at a ﬂow rate of 5 μl per minute. Peptides were resolved at 250 nl/
min ﬂow rate using a linear gradient of 10 to 35% solvent B (0.1% formic acid in
95% acetonitrile) over 120 min on the EASY-Spray column (50 cm × 75 µm ID,
PepMap RSLC C18, and 2 µm C18 particles) (Thermo Scientiﬁc). It was ﬁtted on an
EASY-Spray ion source that was operated at 2.0 kV voltage. Mass spectrometry
analysis was carried out in a data-dependent manner with full scans of m/z 350 to
1500. Both MS and MS/MS were acquired and measured using Orbitrap mass
analyzer. Full MS scans were measured at a resolution of 120,000 at m/z 200.
Precursor ions were fragmented using a higher-energy collisional dissociation
method (35) and detected at a mass resolution of 30,000 at m/z 200. Proteome
Discoverer 2.4 was used for identiﬁcation and quantiﬁcation against uniport_mouse_120119_UP000000589. The search parameters used are as follows: (a)
trypsin (up to two missed cleavages), (b) minimum amino acid length: 6, (c)
minimum peptides for protein: 1, (d) Fixed modiﬁcations TMT6plex on any
N-terminus and Lysis residue, Carbamidomethylation of cysteine, (e) Dynamic
modiﬁcations: Oxydation on Methionine, acetyl on N-terminus, Met-loss on M
and Met loss +acetyl on M and (f) 1% false discovery rate for peptide and protein
levels.
TMT cardiac sarcomere phospho tyrosine proteomics
Sample preparation and TMT pTyr enrichment. Myoﬁlament enriched preparations
were obtained by rinsing freshly isolated hearts in ice-cold PBS (Proteinase Inhibitors Roche 1X and PhosStop 1X, Roche), auricular tissue removed and ventricular tissue minced in ice-cold standard buffer (60 mM KCl, 30 mM Imidazole
pH 7.0, 2 mM MgCl2, Proteinase Inhibitors Roche 1X and PhosStop 1X from
Roche). The ventricular tissues were homogenized with a homogenizer (Omni
tissue homogenizer TH) at maximum speed for 2–3 pulses of 10 seconds with the
solution on ice, centrifuged at 12,000 g for 15 min. The myoﬁlament pellets were
resuspended in a skinning solution (10 mK EGTA 8.2 mM MgCl2, 14.4 mM KCl,
60 mM imidazole pH 7.0, 5.5 mM ATP, 12 mM creatine phosphate, 10 U/mL
creatine phosphokinase, 1% Triton 100X, Proteinase Inhibitors Roche 1X and
PhosStop 1X from Roche) and incubated on ice for 30 min28. Myoﬁlament pellets
were centrifuged at 1100 g for 15 min and washed in the standard buffer. Freshly
isolated myoﬁlament pellets were diluted in standard buffer and quantiﬁed with
Lowery assay. Myoﬁlament proteins (~7 mg) from each mouse heart were resuspended in 8 M urea and 50 mM triethylammonium bicarbonate (TEAB) (Sigma)
followed by reduction with 10 mM dithiothreitol (Sigma) at room temperature for
1 h and alkylation with 30 mM iodoacetamide (Sigma) for 20 min in the dark, see
Fig. 4a–d. The protein samples were then digested overnight at 37 °C using
sequencing grade trypsin (1:50) (Promega). Tryptic peptides were desalted and
labeled with 6-plex isobaric tandem mass tags (TMT) (Thermo Scientiﬁc)
according to the manufacturer’s instructions. The labeling reaction was carried out
for 1 h at room temperature, followed by quenching with 100 mM Tris.HCl (pH
8.0). The digested and labeled peptides were pooled and desalted with C18 SEPPAK (Waters), followed by pTyrsoine enrichment using PTMScan® PhosphoTyrosine Rabbit mAb (P-Tyr-1000) kit (Cell Signaling Technology), see Fig. 4c.
Brieﬂy, the desalted peptides were reconstituted in 1.4 ml of immunoafﬁnity
puriﬁcation (IP) buffer containing 50 mM MOPS pH 7.2, 10 mM sodium phosphate, 50 mM NaCl. Anti-phosphotyrosine antibody (p-Tyr-1000, Cell Signaling
Technology) was mixed with peptide solution and incubated on a rotator at 4 °C
for 2 h. After incubation, the beads were washed with IP buffer and water two and
three times, respectively. The phosphotyrosine peptides were eluted using 0.1%
TFA. The eluted peptide samples were desalted using C18 STAGE tips, vacuum
dried, and kept at −80 °C before LC-MS analysis. From ﬂow-through, a quantiﬁcation of the full proteome was made to serve as a reference for pTyr proteome
ﬁndings.
LC-MS/MS analysis. The phosphotyrosine peptides and non-phosphorylated
peptides were analyzed on Orbitrap Fusion Lumos Tribrid (Thermo Scientiﬁc,
San Jose, CA, USA) coupled with Easy-nanoLC 1200 nanoﬂow liquid chromatography system (Thermo Scientiﬁc). The peptides from each fraction were reconstituted in 10% formic acid and loaded on Acclaim PepMap100 Nano Trap
Column (100 μm × 2 cm) (Thermo Scientiﬁc) packed with 5 μm C18 particles at a
ﬂow rate of 5 μl per minute. Peptides were resolved at 250 nl/min ﬂow rate using a
linear gradient of 10–35% solvent B (0.1% formic acid in 95% acetonitrile) over
95 min on the EASY-Spray column (50 cm × 75 µm ID, PepMap RSLC C18, and
2 µm C18 particles) (Thermo Scientiﬁc) and it was ﬁtted on EASY-Spray ion source
that was operated at 2.0 kV voltage. Mass spectrometry analysis was carried out in a
data-dependent manner with full scans in the range of m/z 350 to 1500. Both MS
and MS/MS were acquired and measured using Orbitrap mass analyzer. Full MS
scans were measured at a resolution of 120,000 at m/z 200. Precursor ions were
fragmented using a higher-energy collisional dissociation method and detected at a
mass resolution of 30,000 at m/z 200.
Peptide search and Identiﬁcation. MaxQuant 1.5 was used for quantitation and
identiﬁcation against a mouse RefSeq database (version 78) supplemented with
frequently observed contaminants. The search parameters used are as follows: (a)
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trypsin as a proteolytic enzyme (with up to two missed cleavages); (b) peptide mass
error tolerance of 10 ppm; (c) fragment mass error tolerance of 0.02 Da; (d) Carbamidomethylation of cysteine (+57.02 Da) and TMT tags (+229.16 Da) on lysine
residue and peptide N-termini as ﬁxed modiﬁcation and oxidation of methionine
(+15.99 Da) and phosphorylation of serine/threonine/tyrosine (+79.96 Da) as
variable modiﬁcations. Two missed cleavages were allowed, and ‘match between
runs’ was enabled. Peptides and proteins were ﬁltered at a 1% false discovery rate.
Proteins with a q-value lower than 0.05 will be considered as differentially
expressed with statistical signiﬁcance.
Echocardiogram. Cardiac morphology and function were assessed by transthoracic
echocardiography using a high-resolution high-frequency system (Vevo 2100,
VisualSonics, Canada) equipped with 40 MHz ultrasound probe in conscious
mice22,53. Mechanical and chemical chest hair removal was performed by shaving
and using a commercially available depilatory agent. Core temperature, monitored
via a rectal probe, was maintained at 36.5–37 °C using a heating lamp. Parasternal
long and short-axis views of the heart were captured in both B and M-modes at
optimized frame rates. LV end-diastolic (LVIDd, mm) and end-systolic (LVIDs,
mm) internal diameters, the end-diastolic wall thickness of both interventricular
septum (IVS, mm) and LV posterior wall (LVPW, mm), LV ejection fractions (EF,
%) and fractional shortening (FS, %) were measured using M-Mode in long-axis
view. Relative wall thickness (RWT), a measure of hypertrophy, was calculated as
IVSd+LVPWd/LVID. Pulsed-Doppler recordings at the mitral inﬂow, left ventricular outﬂow and basal septum was recorded. Digital images were stored and
analyzed ofﬂine using commercially available Vevo LAB software (VisualSonics,
Canada). An experienced echocardiography technician blinded to experimental
groups performed all the measurements.

Statistical analysis
Western Blot densitometry. The density of the bands was measured using ImageJ
software and the area under the curve corresponding to the bands of pSRC, SRC,
GAPDH, TnI, and total pTyr was calculated. Then, pTyr/TnI, SRC/GAPDH,
pSRC/GAPDH, and pSRC/SRC ratios were calculated and the ratios were compared between groups using one-way ANOVA.
Mean orientation and circular variance from histological samples comparison. To
characterize the effects of AG-825 on cardiomyocyte disarray, we used the web
graphic user interphase CytoSpectre32 to determine the local orientation of cardiomyocytes across histological sections. In randomly chosen regions, the myocyte
mean orientation angle circular variance was calculated. Statistical comparison
between groups (Ntg+Vehicle, Ntg+AG825, TgErbB2+Veh, TgErbB2 + AG825)
was made with one-way ANOVA.

Systems biology analysis. Statistical analysis of the label-free dataset was performed using Perseus software54. Peptides with less than 50% of detection were
ﬁltered, and the missing values of the intensities of the reminding peptides were
ﬁlled with k-nearest neighbors. Then, the log2 intensities were normalized by
median subtraction, ANOVA, and false discovery rate calculations. A heatmap was
used to visualize the unsupervised hierarchical clustering of proteins with a p-value
<0.05 by ANOVA test. For statistical analysis of the TMT-labeled proteomics data
collected, we followed the workﬂow of Foster et al.21, with few modiﬁcations. First,
Partek software was used to calculate each peptide intensity’s p-values, q-values,
fold change, and ratio. Phosphosites with less than 50% of missing density values
were subjected to statistical analysis, and the reminding missing values were ﬁlled
with the k-nearest neighbors. Then, a normalization of the Log2 densities by
median subtraction and determined the fold-change, ratio, and statistical signiﬁcance (q and p values), from each of the selected phosphosites of the dataset.
The volcano plots were made with GraphPad Prism 7®. Unsupervised PCA was
used in both data sets separately with Partek® software. The dataset was segregated
along with each component concerning the pTyr abundance (normalized, mean =
0, variance = 1).
Normalization to the full proteome performed by log2 intensity subtraction was
done, followed by a two-sided t test and the moderated p-values and q-values
calculation using an algorithm developed by Herbrich et al.55; R software was used
for this analysis.
Pathway enrichment analysis. The hypergeometric p-value was used to identify the
signiﬁcantly enriched processes in the proteins and phosphosites that are differentially phosphorylated between case and control samples. For this purpose,
MsigDB23 was used to analyze the protein level pathways and PTMsigDB24 to
analyze the processes at the site level. The population/background for which the
enrichment is calculated is restricted to all the proteins in which their sites are
quantiﬁed in the phosphoproteomics experiment, rather than all universally known
proteins/phosphosites.
KSEA. The KSEA seeks to identify kinases whose targets exhibit signiﬁcantly
altered phosphorylation levels in a given condition. KSEA scores each kinase k with
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a set of substrates S as follows:

pﬃﬃﬃﬃﬃ
  PÞ
 * jSj
ðP
scoreðkÞ ¼ S
σ
 S Den otes the average log2 of the fold change of all the substrates of kinase
where P
 and σ represent the average and standard deviation of log2 of the fold
k, and P
change of all the identiﬁed phosphosites in the dataset. KSEA was performed on
the identiﬁed modules by restricting S to the substrates in the module instead of all
substrates in the dataset. The data provided by PhosphoSitePLUS30 was used as the
reference for kinase-substrate associations. This tool is available from Dr. M. Ayati
website: https://faculty.utrgv.edu/marzieh.ayati/software.html
Module Identiﬁcation. First, networks were created in which nodes represent
proteins and edges represent the PPI obtained from BioGRID22,56. The proteins
were assigned a score in the networks by computing the average fold change of
phosphosites residing on each protein obtained from experiments individually (i.e.,
Ntg, TgErbB2, and R403Q-αMyHC Tg). Then MoBaS22 was applied to identify
subnetworks of highly connected and differentially phosphorylated proteins. For
visualization of subnetworks, the proteins are colored based on the average fold
change of that protein in different conditions. If a protein in one dataset is not
identiﬁed in another dataset, the node is represented in gray color.
Echocardiography comparison. One-way ANOVA was used to compare differences
between groups to analyze the echocardiography data. For the effect of AG-825 or
vehicle treatments, the pre- post- Treatment, we used a t-test.
Statistics and reproducibility. Experiments were conducted in replicates (see
“Methods” section). Mascot (version2.3) was used for peptide identiﬁcation from
MS raw data, and MaxQuant (version 1.5) was used for quantiﬁcation. Statistical
analysis was performed using R (version 4.0), Partek Genomics Suit (version 7.0),
GraphPad Prism 7.0, and Perseus (version 1.5). Additional details of data processing are described in the “Methods” section.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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